Trial Profile
MIRACLE (Methotrexate Inadequate Response Patient With Rheumatoid Arthritis Treated by Adalimumab in Combination With Low-dose Methotrexate) Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Methotrexate (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms MIRACLE
- 03 Jun 2023 Primary endpoint has not been met (Simple Disease Activity Index (SDAI) Remission Rate (ADA/MTX-Reduced Dose Group)) , according to Results presented at the 24th Annual Congress of the European League Against Rheumatism
- 03 Jun 2023 Primary endpoint has not been met (Simple Disease Activity Index (SDAI) Remission Rate (ADA/MTX-Maximum Tolerated Dose Group)) , according to Results presented at the 24th Annual Congress of the European League Against Rheumatism
- 03 Jun 2023 Results assessing association between the concentrations of MTX-PGs with efficacy and safety through week 48 presented at the 24th Annual Congress of the European League Against Rheumatism